Skip to main content

Table 1 Physical profiles of control, placebo-group, and DOCA-salt group rats

From: Transiently proliferating perivascular microglia harbor M1 type and precede cerebrovascular changes in a chronic hypertension model

Group Body weight (g) Systolic blood pressure (mmHg) Heart rate (/min) Symptoms
Control 0W 165 ± 4.3 113.0 ± 2.8 427.3 ± 38 None
Placebo 2W 261 ± 3.9* 116.3 ± 3.4 414.3 ± 31 None
3W 295 ± 16* 125.0 ± 3.7 412.3 ± 33 None
4W 330 ± 11* 130.0 ± 7.3 413.0 ± 12 None
DOCA 2W 250.3 ± 8.3* 183.3 ± 24* 416.0 ± 50 None
3W 253.0 ± 30* 204.3 ± 18* 407.3 ± 9.5 Hemiparesis, bleeding from the tail vein, and loss of appetite
4 W 225.0 ± 14* 207.0 ± 30* 450.0 ± 29 Severe inactive state
  1. Rats administrated with DOCA-salt or placebo for 2 weeks (DOCA2W or Placebo2W), 3 weeks (DOCA3W or Placebo3W), and 4 weeks (DOCA4W or Placebo4W) were analyzed. Values are expressed as means ± SEM (n = 3 in each group). Statistical significance was expressed as *p < 0.05 relative to the control by using t test